Author:
Wu Yangying,Zhao Ziya,Kang Shaolei,Zhang Lijuan,Lv Fajin
Abstract
Intracranial aneurysm (IA) counts are increasing yearly, with a high mortality and disability after rupture. Current diagnosis and treatment rely on costly equipment, lacking effective indicators for progression prediction and specific drugs for treatment. Recently, peripheral blood biomarkers, as common clinical test samples, reflecting the immune and inflammatory state of the body in real-time, have shown promise in providing additional information for risk stratification and treatment in IA patients, which may improve their outcomes after aneurysm rupture through anti-inflammatory therapy. Therefore, this paper reviewed the progress of potential biomarkers of IAs, including inflammatory blood indicators, cytokines, and blood lipids, aiming to aid individual management and therapy of aneurysms in clinical practices.
Subject
Neurology (clinical),Neurology
Reference86 articles.
1. Saccular intracranial aneurysm: pathology and mechanisms;Frosen;Acta Neuropathol,2012
2. Inflammatory mediators in vascular disease: identifying promising targets for intracranial aneurysm research;Sawyer;Mediat Inflamm,2015
3. Prevalence of Unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: A systematic review and Meta-analysis;Vlak;Lancet Neurol,2011
4. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: A pooled analysis of six prospective cohort studies;Greving;Lancet Neurol,2014
5. Risk analysis of Unruptured intracranial aneurysms: prospective 10-year cohort study;Murayama;Stroke,2016
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献